Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant

Cytotherapy

Volumn 14, Issue 1, 2012, Pages 7-11

  Sili, Uluhan ^a,b   Leen, Ann M ^a   Vera, Juan F ^a   Gee, Adrian P ^a   Huls, Helen ^a   Heslop, Helen E ^a   Bollard, Catherine M ^a   Rooney, Cliona M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

adenovirus; CMV; Cytotoxic T cells (CTLs); EBV; HSCT; Immunotherapy; viral infections

Indexed keywords

ADENOVIRUS; ADENOVIRUS INFECTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL EXPANSION; COMPUTER PROGRAM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DAUDI CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GOOD MANUFACTURING PRACTICE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 83755188603     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.636963     Document Type: Article

References (20)

1. Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010;10: 337-51.
2. Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specifi c cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:677-86. (Pubitemid 46813584)
3. Leen AM, Bollard CM, Myers GD, Rooney CM. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:243-51. (Pubitemid 43273709)
4. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immunetherapy in haematological practice. Br J Haematol. 2008; 143:169-79.
5. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specifi c for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-6. (Pubitemid 44527351)
6. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stemcell transplantation with virus-specifi c T-cell lines. Lancet. 2003;362:1375-7. (Pubitemid 37338339)
7. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specifi c T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-22. (Pubitemid 35332029)
8. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.nEngl J Med. 1995;333:1038-44.
9. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modifi ed virus-specifi c T lymphocytes to control Epstein - Barr-virusrelated lymphoproliferation. Lancet. 1995;345:9-13.
10. Leen A, Ratnayake M, Foster A, et al. Contact-activated monocytes: Effi cient antigen presenting cells for the stimulation of antigen-specifi c T cells. J Immunother. 2007;30:96-107. (Pubitemid 46052208)
11. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specifi c T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33:305-15.
12. Lapteva N, Vera JF. Optimization manufacture of virus- and tumor-specifi c T cells. Stem Cells Int. 2011;2011:434392.
13. 8+ T cells. Blood. 2004; 104:2432-40. (Pubitemid 39331844)
14. Gerdemann U, Christin AS, Vera JF, et al. Nucleofection of DCs to generate multivirus-specifi c T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009;17:1616-25.
15. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specifi c evolution of human CD8(- ) T cell responses from primary to persistent phases of Epstein - Barr virus infection. J Exp Med. 2002;195:893-905.
16. Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein - Barr virus latent-cycle proteins for human CD4(- ) T-helper 1 responses. J Virol. 2001;75:8649-59. (Pubitemid 32768969)
17. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein - Barr virus. Annu Rev Immunol. 2007;25:587-617. (Pubitemid 46697918)
18. Leen AM, Christin A, Khalil M, et al. Identifi cation of hexonspecifi c CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008;82:546-54. (Pubitemid 350309169)
19. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein - Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114:4283-92.
20. Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virusspecifi c T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700-2.